These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34105901)

  • 1. A systematic review of myasthenia gravis complicated with myocarditis.
    Cheng W; Sun T; Liu C; Zhou Z; Duan J; Zhao Y; Yang M; Chen P
    Brain Behav; 2021 Aug; 11(8):e2242. PubMed ID: 34105901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
    Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
    Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
    Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
    Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
    Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
    J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
    Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
    Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.
    Wang C; Zeng H; Fang W; Song L
    Invest New Drugs; 2023 Apr; 41(2):333-339. PubMed ID: 36988830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis.
    Tanabe J; Watanabe N; Endo A; Nagami T; Inagaki S; Tanabe K
    Intern Med; 2021 Feb; 60(4):569-573. PubMed ID: 33028770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
    Leaver PJ; Jang HS; Vernon ST; Fernando SL
    BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heart disease in myasthenia gravis].
    Mygland A; Gilhus NE; Hofstad H; Aarli JA; Thunold S
    Tidsskr Nor Laegeforen; 1990 Apr; 110(10):1209-11. PubMed ID: 2333646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver Cancer with Overlapping Myasthenia Gravis, Myocarditis, Seronegative Autoimmune Autonomic Ganglionopathy, and Myositis Symptoms Induced by Atezolizumab.
    Shibuya R; Baba K; Furuta R; Maesaka H; Hirosawa H; Bando T; Oshima A; Onoda H; Nukui T; Dougu N; Joho S; Nakatsuji Y
    Intern Med; 2024 Aug; 63(15):2193-2198. PubMed ID: 38171860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
    Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event.
    Lin X; Guan W; Li B; Deng H; Chen Y; Yang Y; Qiu G; Xie X; Zhou C
    Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):780-787. PubMed ID: 37339370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.
    Gao L; Li X; Guo Z; Tang L; Peng J; Liu B
    Medicine (Baltimore); 2022 Dec; 101(49):e32240. PubMed ID: 36626474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.
    Rhee JY; Torun N; Neilan TG; Guidon AC
    Oncologist; 2022 May; 27(5):e402-e405. PubMed ID: 35348772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
    Cham J; Ng D; Nicholson L
    J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
    Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexisting of myasthenia gravis and fulminant myocarditis induced by nivolumab in a patient with ureteral epithelial cancer.
    Zhang J; Li J; Zhai L; Lin L
    Neuro Endocrinol Lett; 2021 Oct; 42(6):383-386. PubMed ID: 34713689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitor-Induced Myocarditis With Concurrent Myasthenia Gravis.
    Kuniyoshi J; Huang R; Choi H; Bernas M; Techasatian W; Nishimura Y
    Can J Cardiol; 2023 Nov; 39(11):1646-1648. PubMed ID: 37330137
    [No Abstract]   [Full Text] [Related]  

  • 19. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review.
    Chen Y; Jia Y; Liu Q; Shen Y; Zhu H; Dong X; Huang J; Lu J; Yin Q
    Ann Palliat Med; 2021 Jul; 10(7):8512-8517. PubMed ID: 34263614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.
    Nelke C; Pawlitzki M; Kerkhoff R; Schroeter CB; Aktas O; Neuen-Jacob E; Polzin A; Meuth SG; Ruck T
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37884388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.